

# High Purity Excipients for Parenteral Formulation

## High Purity Excipients for Parenteral Formulation

 The parenteral application requires excipients of the highest quality standards. Solubilizers and co-solvents are the most widely employed excipients in the formulation of parenterals.

BASF offers a wide range of high-quality solubilization excipients and has unparalleled experience in quality and regulatory affairs, as well as solubility enhancement strategies.

## **Quality & Regulatory**

The quality and regulatory benchmarks BASF applies to its parenteral excipients are comprised of:

- Manufacturing according to IPEC-PQG GMP
- Compendial compliance covering current and proposed major global pharmacopoeia standards
- Endotoxin & microbial testing
- Elemental impurity limits as per ICH Q3D
- Stability studies as per ICH guidelines
- Regulatory documentation
- Registration & submission support
- Non-clinical safety data

#### Production

Our excipients for parenterals are produced in Germany by qualified and experienced employees in line with the appropriate high-quality standards including documentation, equipment, utilities and personnel.

### Solubilization

We offer a range of highly effective solubilization excipients for parenterals. Our experts have access to industry-leading tools and analytics such as our in-house developed highthroughput formulation robot, comprehensive solubilization screening, supersaturation and crystallization precipitation kinetics, as well as biorelevant analysis. Coupled with a deep and profound understanding of our excipients, we are in an excellent position to enable our customers to tackle their solubilization challenges rapidly and efficiently.

Product	Functionality	Monograph title / Chemical category	FDA IID listing
Kolliphor® HS 15	Nonionic solubilizer and emulsifier (surfactant; HLB = 15)	Macrogol 15 Hydroxystearate (Ph.Eur.) and Polyoxyl 15 Hydroxystearate (USP/NF) / Polyethoxylated 12-hydroxystearic acid	Yes*
Kolliphor® ELP	Nonionic solubilizer and emulsifier (surfactant; HLB = 12-14)	Macrogolglycerol ricinoleate (Ph.Eur.) and Polyoxyl 35 castor oil (USP/NF) / Polyethoxylated castor oil	Yes
Kollidon <sup>®</sup> 12 PF	Solubilizer by complexation	Povidone (Ph.Eur., USP/NF and JP) / Synthetic polymer	Yes
Kollidon <sup>®</sup> 17 PF	Solubilizer by complexation	Povidone (Ph.Eur., USP/NF and JP) / Synthetic polymer	Yes

Kolliphor<sup>®</sup> HS 15 is used in a recently FDA approved parenteral drug.
For over ten years Kolliphor<sup>®</sup> HS 15 has been used in injectable drugs in both Canada and Europe.





## Our service offer

For our parenteral excipients we provide comprehensive documentation including toxicological assessments, regulatory & quality packages, certificates and more.

Please contact us regarding your specific applications and needs:

North America Shaukat Ali shaukat.ali@basf.com

South America Vinicius Steffen vinicius.steffen@basf.com Asia Pacific Rajkiran Narkhede rajkiran.narkhede@basf.com

Europe, Middle East, Africa Nadezhda Romanova nadezhda.romanova@basf.com

## For more information visit us on **www.pharma.basf.com**

For sample requests contact us at pharma-solutions@basf.com

This document, or any information provided herein does not constitute a legally binding obligation of BASF and has been prepared in good faith and is believed to be accurate as of the date of issuance. Unless expressly agreed otherwise in writing in a supply contract or other written agreement between you and BASF:

(a) To the fullest extent not prohibited by the applicable laws, BASF EXPRESSLY DISCLAIMS ALL OTHER REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, BY FACT OR LAW, INCLUDING ANY IMPLIED WARRANTIES, REPRESENTATIONS OR CONDITIONS OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SATISFACTORY QUALITY, NON-INFRINGEMENT, AND ANY REPRESENTATIONS, WARRANTIES, CONDITIONS OR GUARANTEES, ARISING FROM STATUTE, COURSE OF DEALING OR USAGE OF TRADE and BASF HEREBY EXPRESSLY EXCLUDES AND DISCLAIMS ANY LIABILITY RESULTING FROM OR IN CONNECTION WITH THIS DOCUMENT OR ANY INFORMATION PROVIDED HEREIN, including, without limitation, any liability for any direct, consequential, special, or punitive damages relating to or arising there from, except in cases of (i) death or personal injury to the extent caused by BASF's sole negligence, (ii) BASF's willful misconduct, fraud or fraudulent misrepresentation or (iii) any matter in respect of which it would be unlawful for BASF to exclude or restrict liability under the applicable laws;

(b) Any information provided herein can be changed at BASF's sole discretion anytime and neither this document nor the information provided herein may be relied upon to satisfy from any and all obligations you may have to undertake your own inspections and evaluations;

(c) BASF rejects any obligation to, and will not, automatically update this document and any information provided herein, unless required by applicable law; and

(d) The user is responsible for confirming that the user has retrieved the most current version of this document from BASF as appropriate.

# 

#### Meet your Virtual Pharma Assistants!

ZoomLab<sup>™</sup>, RegXcellence<sup>®</sup>, and MyProductWorld, your interactive guides for optimizing drug formulations, navigating quality and regulatory compliance, and browsing ingredients.

Learn more and sign up at https://info-mypharma.basf.com/